focus -WSS

focus

author：focus 2025-09-27 10:05:01 - browse：9733

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： U.S. death rates show how politics are affecting public health

explore

knowledge

explore

WSS

Lawsuit highlights wrinkle for disputes over surprise medical bills

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

J&J reports mixed data on next

Louisiana bill approved classifying abortion pills as controlled substances

Bird flu makes raw milk dangerous to consume, mouse study finds

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Hepatitis C has a cure — but many Americans still lack access to it

U.S. death rates show how politics are affecting public health

How one medical school became remarkably diverse

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Novavax promises a turnaround & Lilly roils the obesity market

European officials brace for rough respiratory virus season

How to save PrEP access — and even expand it

The biotech scorecard for Q4: 16 stock

Walensky prepares to leave CDC — and Congress — behind

Hospitals need to get ahead of regulations on climate change

entertainment

Stop Congress from blocking public access to science

2023 Nobel Prize in Medicine goes to Karikó and Weissman

European officials brace for rough respiratory virus season

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Nobel honors Karikó and Weissman's enduring partnership

6 solutions to address cancer drug shortages and others

explore

knowledge

explore

Wikipedia